Compounds / Metabolic / Survodutide

Survodutide

Survodutide (Dual GLP-1/Glucagon Agonist — BI 456906)
MetabolicExtensively StudiedFDA: Not approved; Phase III trials

Overview

Phase III trials. Phase II: significant weight loss and MASH improvement. MASH indication potentially first-in-class dual agonist approval.

Mechanism of Action

Dual GLP-1R/glucagon receptor agonist (Boehringer Ingelheim). Glucagon component enhances energy expenditure and hepatic fat reduction. Phase III for obesity and MASH (metabolic dysfunction-associated steatohepatitis).

Pharmacokinetics

Half-life
6.5 days
Peak (Tmax)
2 days
Cleared
~32.5 days

Molecular Profile

Molecular weight
~4.5 kDa

Key Research Findings

Dual GLP-1/glucagon; MASH treatment potential; obesity; Phase III ongoing.

Published Research

NEJM (2024)
Sanyal AJ et al. Survodutide for MASH: Phase II trial results
View source

Related Metabolic Compounds

SemaglutideTirzepatideRetatrutideCagrilintideMazdutideBioglutide
Clinical Guidance

Research data is not a treatment plan. If you are considering Survodutide, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Survodutide? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals